180 related articles for article (PubMed ID: 23408880)
1. The timing and targeting of treatment in influenza pandemics influences the emergence of resistance in structured populations.
Althouse BM; Patterson-Lomba O; Goerg GM; Hébert-Dufresne L
PLoS Comput Biol; 2013; 9(2):e1002912. PubMed ID: 23408880
[TBL] [Abstract][Full Text] [Related]
2. The effect of population structure on the emergence of drug resistance during influenza pandemics.
Débarre F; Bonhoeffer S; Regoes RR
J R Soc Interface; 2007 Oct; 4(16):893-906. PubMed ID: 17609176
[TBL] [Abstract][Full Text] [Related]
3. Drivers and consequences of influenza antiviral resistant-strain emergence in a capacity-constrained pandemic response.
Dafilis MP; Moss R; McVernon J; McCaw J
Epidemics; 2012 Dec; 4(4):219-26. PubMed ID: 23351374
[TBL] [Abstract][Full Text] [Related]
4. Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
Handel A; Longini IM; Antia R
J Theor Biol; 2009 Jan; 256(1):117-25. PubMed ID: 18952105
[TBL] [Abstract][Full Text] [Related]
5. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
[TBL] [Abstract][Full Text] [Related]
6. Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales.
Patterson-Lomba O; Althouse BM; Goerg GM; Hébert-Dufresne L
PLoS One; 2013; 8(3):e59529. PubMed ID: 23555694
[TBL] [Abstract][Full Text] [Related]
7. Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.
Hollingsworth TD; Klinkenberg D; Heesterbeek H; Anderson RM
PLoS Comput Biol; 2011 Feb; 7(2):e1001076. PubMed ID: 21347316
[TBL] [Abstract][Full Text] [Related]
8. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.
Arino J; Bowman CS; Moghadas SM
BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634
[TBL] [Abstract][Full Text] [Related]
9. The global spread of drug-resistant influenza.
Chao DL; Bloom JD; Kochin BF; Antia R; Longini IM
J R Soc Interface; 2012 Apr; 9(69):648-56. PubMed ID: 21865253
[TBL] [Abstract][Full Text] [Related]
10. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
Hurt AC; Chotpitayasunondh T; Cox NJ; Daniels R; Fry AM; Gubareva LV; Hayden FG; Hui DS; Hungnes O; Lackenby A; Lim W; Meijer A; Penn C; Tashiro M; Uyeki TM; Zambon M;
Lancet Infect Dis; 2012 Mar; 12(3):240-8. PubMed ID: 22186145
[TBL] [Abstract][Full Text] [Related]
11. The potential for multidrug-resistant influenza.
van der Vries E; Schutten M; Boucher CA
Curr Opin Infect Dis; 2011 Dec; 24(6):599-604. PubMed ID: 22001947
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological consequences of household-based antiviral prophylaxis for pandemic influenza.
Black AJ; House T; Keeling MJ; Ross JV
J R Soc Interface; 2013 Apr; 10(81):20121019. PubMed ID: 23389899
[TBL] [Abstract][Full Text] [Related]
13. Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza.
Dimitrov NB; Goll S; Hupert N; Pourbohloul B; Meyers LA
PLoS One; 2011 Jan; 6(1):e16094. PubMed ID: 21283514
[TBL] [Abstract][Full Text] [Related]
14. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance.
Alexander ME; Dietrich SM; Hua Y; Moghadas SM
J Theor Biol; 2009 Jul; 259(2):253-63. PubMed ID: 19344730
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment for pandemic influenza: assessing potential repercussions using a seasonally forced SIR model.
Towers S; Vogt Geisse K; Zheng Y; Feng Z
J Theor Biol; 2011 Nov; 289():259-68. PubMed ID: 21867715
[TBL] [Abstract][Full Text] [Related]
16. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.
Handel A; Longini IM; Antia R
Epidemics; 2009 Sep; 1(3):185-95. PubMed ID: 20161493
[TBL] [Abstract][Full Text] [Related]
17. Modeling the effects of drug resistant influenza virus in a pandemic.
Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
Handel A; Longini IM; Antia R
PLoS Comput Biol; 2007 Dec; 3(12):e240. PubMed ID: 18069885
[TBL] [Abstract][Full Text] [Related]
19. Likely effectiveness of pharmaceutical and non-pharmaceutical interventions for mitigating influenza virus transmission in Mongolia.
Bolton KJ; McCaw JM; Moss R; Morris RS; Wang S; Burma A; Darma B; Narangerel D; Nymadawa P; McVernon J
Bull World Health Organ; 2012 Apr; 90(4):264-71. PubMed ID: 22511822
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Nguyen HT; Fry AM; Gubareva LV
Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
